ARTICLE | Company News
Alzamend disclosed that in May the university granted the newco exclusive, worldwide rights to a patent related to the biotech's CAO22W, a preclinical candidate for Alzheimer's disease (AD). The paten...
Alzamend disclosed that in May the university granted the newco exclusive, worldwide rights to a patent related to the biotech's CAO22W, a preclinical candidate for Alzheimer's disease (AD). The paten...